Bispecific J&J Drug Wins Speedy FDA Approval for Treating Head & Neck Cancer
Posted
Frank Vinluan (via MedCity News)
Accelerated FDA approval of Johnson & Johnson’s Rybrevant Faspro covers advanced cases of head and neck cancer. The bispecific antibody was initially approved for treating certain lung cancers.
The post Bispecific J&J Drug Wins Speedy FDA Approval for Treating Head & Neck Cancer appeared first on MedCity News.
